Iinuma, K.; Enomoto, T.; Kawada, K.; Fujimoto, S.; Ishida, T.; Takagi, K.; Nagai, S.; Ito, H.; Kawase, M.; Nakai, C.;
et al. Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. J. Clin. Med. 2021, 10, 5325.
https://doi.org/10.3390/jcm10225325
AMA Style
Iinuma K, Enomoto T, Kawada K, Fujimoto S, Ishida T, Takagi K, Nagai S, Ito H, Kawase M, Nakai C,
et al. Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. Journal of Clinical Medicine. 2021; 10(22):5325.
https://doi.org/10.3390/jcm10225325
Chicago/Turabian Style
Iinuma, Koji, Torai Enomoto, Kei Kawada, Shota Fujimoto, Takashi Ishida, Kimiaki Takagi, Shingo Nagai, Hiroki Ito, Makoto Kawase, Chie Nakai,
and et al. 2021. "Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab" Journal of Clinical Medicine 10, no. 22: 5325.
https://doi.org/10.3390/jcm10225325
APA Style
Iinuma, K., Enomoto, T., Kawada, K., Fujimoto, S., Ishida, T., Takagi, K., Nagai, S., Ito, H., Kawase, M., Nakai, C., Kawase, K., Kato, D., Takai, M., Nakane, K., Kameyama, K., & Koie, T.
(2021). Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. Journal of Clinical Medicine, 10(22), 5325.
https://doi.org/10.3390/jcm10225325
